参松养心胶囊治疗室性早搏随机对照试验的系统评价

Systematic review on randomized controlled trials for treatment of ventricular premature beat(VPB) by ShensongYangxin capsule

目的:探讨参松养心胶囊与对照药物治疗室性早搏的有效性及安全性的差异。方法:应用Meta分析21篇关于参松养心胶囊与其它常用治疗室性早搏药治疗室性早搏的研究文献,对其有效性及安全性进行同质性检验及合并效应量的估计。结果:同质性检验:心电图疗效有效性:χ2=25.20,df=17,P=0.090;临床疗效有效性:χ2=26.10,df=11,P=0.006;室性早搏疗效有效性:χ2=7.13,df=5,P=0.211;安全性1χ2=31.14,df=20,P=0.053,安全性2χ2=30.37,df=20,P=0.064。合并效应量的估计,有效性:心电图疗效OR合并=1.04,OR合并95%可信区间为[1.00,1.09]。临床疗效OR合并=1.33,OR合并95%可信区间为[1.19,1.48]。室性早搏疗效OR合并=1.25,OR合并95%可信区间为[1.13,1.39]。安全性1OR合并=0.38,OR合并95%可信区间为[0.28,0.52];安全性2OR合并=0.39,OR合并95%可信区间为[0.29,0.52]。结论:参松养心胶囊治疗室性早搏有优于对照组的趋势,安全性比较优于对照组且有统计学差异。

AIM：To evaluate the curative effect difference between ShensongYangxincapsule and Control Group and the safety of them on ventricular premature beat（VPB）. METHODS：Meta-analysis of 21-ShensongYangxin Capsule on the parameters commonly used treatment of VPB and other research literature on drug treatment of VPB,its effectiveness and safety for homogeneity test and the combined effect size estimate. RESULTS：Homogeneity test：Clinical effectiveness of the ECG：χ2=25.20,df=17,P=0.090; Clinical effectiveness：χ2=26.10,df=11,P=0.006; Clinical effectiveness of ventricular premature beats：χ2=7.13,df=5,P=0.211;Security 1 χ2=31.14,df=20,P=0.053,Security 2 χ2=30.37,df=20,P=0.064. Combined effect size estimates：Effectiveness：Clinical effectiveness of the ECG：OR affiliate=1.04,95% confidence interval of OR was [1.00,1.09],Clinical effectiveness：OR affiliate=1.33,95% confidence interval of OR was [1.19,1.48],Clinical effectiveness of ventricular premature beats：OR affiliate=1.25,95% confidence interval of OR was [1.13,1.39],Security 1 ：OR affiliate=0.38,95% confidence interval of OR was [0.28,0.52],Security 2：OR affiliate=0.39,95% confidence interval of OR was [0.29,0.52]. CONCLUSION：The treatment of VPB ShensongYangxin capsule is better than the control group,Comparison of safety is also better control group and there is a significant difference.